Power of the Dream Ventures Inc. announced earnings results for the first quarter ended March 31, 2009. For the quarter, the company reported net income of $580,878. In contrast, the company posted a net income of $732,455 for the same quarter in the previous year.

Power of the Dream Ventures Inc. to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis. The DermaPrep Transdermal Delivery Device supports safe, needle-free administration of liquid formulations in both general hospital and clinical settings. To facilitate the penetration of substances, the skin is cleansed and exfoliated prior to application of the empty patch that serves to retain the liquid in a moist environment. DermaPrep clinical data has been obtained via administration of pDNA-encoded antigens formulated to nanoparticles. Genetic Immunity's proprietary Nanomedicine formulation (antigens, pDNA, proteins, peptides, etc.) is delivered topically with DermaPrep, targeting the body's professional antigen presenting cells, the lymph node dendritic cells, to induce potent immune responses.

Power of the Dream Ventures Inc. presented Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis. Phase 1 trial results for Genetic Immunity's DermaVir Patch HIV vaccine. Genetic Immunity's proprietary DermaVir Patch nanomedicine has been developed to attenuate clinical disease in HIV-infected individuals by induction of long-lasting, HIV-specific T-cells. Preclinical studies on SIV-infected and naive macaques demonstrated that the potent T cell response induced by DermaVir is associated with clinical benefits, including viral load reduction and extended survival. Phase 1 human data for safety and immunogenicity was presented at the 15th Conference on Retroviruses and Opportunistic Infections. Nine HIV infected individuals on fully suppressive HAART were treated a single-time with an increasing number of DermaVir nanomedicine containing 0.1, 0.4 and 0.8 mg of multiple HIV genes encoded plasmid DNA. HAART was maintained during a one-year follow-up. Safety was assessed with standard clinical evaluation, laboratory assays and dermatological analysis of skin reaction. HIV-specific (gag, tat, rev) effector T cells were measured by standard ELISPOT and memory T cells with high proliferative capacity PHPC assay as published in J Immunol 2008, 180: 5907-5915. All DermaVir Patch doses were safe and well tolerated. In all patients, plasma HIV RNA, CD4 and CD8 counts remained in the pre-vaccination level throughout the study. The magnitude of gag-specific memory T cells (PHPC counts) increased from < 200 (baseline) to 2,500-21,500 and 3,000-37,000 at the end of week 48, when administered in medium (0.4mg) and high dose (0.8mg) amounts. The broadening of T cell response was demonstrated by the induction of new rev-and tat-specific memory T cells>